Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
(NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECH TM performance as well as potentially stake new intellectual property claims
Normal enzymes do not exclude elevated SAH, low glutathione or impaired metabolic reserve
Rise of Dual and Triple Agonists: Beyond GLP-1, newer drugs target GIP and glucagon receptors for enhanced efficacy (e.g., Tirzepatide, Retatrutide)
Additionally, p53 could transactive spermidine/spermine N1-acetyltransferase 1 (SAT1), a rate-limiting enzyme in polyamine catabolism
Images are shown for informational purposes only
US$ 24.58
US$ 24.07
US$ 29.55
US$ 28.97
US$ 24.41
US$ 27.28
US$ 29.94
US$ 23.47
US$ 28.48
US$ 20.19
